



Atty. Dkt. No. 033236-0116

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Peter ANDREWS et al.  
Title: PLURIPOTENTIAL CELLS-1  
Appl. No.: 09/913,853  
Filing Date: 12/20/2001  
Examiner: Thaian N. TON  
Art Unit: 1632

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

06/24/2004 JBALINAN 00000120 09913853

01 FC:1806

180.00 0P

**RELEVANCE OF EACH DOCUMENT**

The relevance of the foreign-language document is described in the present specification. An English translation of the foreign-language document is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**FEE**

A fee in connection with submission of a supplemental information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

22 June 2004

By

S. A. Bent

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	09/913,853
Date Submitted: June 22, 2004		<b>Filing Date</b>	12/20/2001
(use as many sheets as necessary)		<b>First Named Inventor</b>	Peter ANDREWS
		<b>Group Art Unit</b>	1632
		<b>Examiner Name</b>	Thaian N. TON
<b>Sheet</b>	3	<b>Attorney Docket Number</b>	033236-0116

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Claudio M. CALDERERA et al., "Regulation of Ribonucleic Acid Sythesis by Polyamines", Biochem. J. (1975) 152, pp. 91-98.	
		K.H.S. CAMPBELL et al., "Sheep cloned by nuclear transfer from a cultured cell line", Nature, vol. 380, 3/1996, pp. 64-65.	
		S.B. CARTER, "Effects of Cytochalasins on Mammalian Cells", Nature, 213, January 21, 1967, pp. 261-264.	
		C. Stephen DOWNES et al., "Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 8895-8899, 1991.	
		T. EGE et al., "Cell Fusion with Enucleated Cytoplasms", Nobel 23 (1973) pp. 189-194.	
		T. EGE et al., "Preparation of microcells by enucleation of micronucleate cells", Exptl. Cell. Res. 87 (1974), pp. 378-382.	
		T. EGE et al., "Introduction of nuclei and micronuclei into cells and enucleated cytoplasms by Sendai virus induced fusion", Exptl. Cell Res. 88 (1974) pp. 428-432.	
		T. EGE et al., "Viability of cells reconstituted by virus-induced fusion of minicells with anucleate cells", Exptl. Cell Res. 94 (1975) pp. 469-473.	
		W. ENGSTRÖM et al., "Growth Factors and the Control of Human Teratoma Cell Proliferation", Recent Results in Cancer Research, Vol. 123, 1991, pp. 145-153.	
		Bruce A. FENDERSON et al., "Glycolipid Core Structure Switching from Globo- to Lacto- and Ganglio-Series during Retinoic Acid-Induced Differentiation of TERA-2-Derived Human Embryonal Carcinoma Cells", Developmental Biology, 122, (1987), pp. 21-34.	
		Josef FULKA Jr. et al., "Noninvasive Chemical Enucleation of Mouse Oocytes", Molecular Reproduction and Development, 34, pp. 427-430 (1993).	
		Robert D. GOLDMAN et al., "Preservation of Normal Behavior by Enucleated Cells in Culture", Proc. Nat. Acad. Sci. USA, Vol. 70, No. 3, pp. 750-754 (1973).	
		Eva GÖNCZÖL et al., "Cytomegalovirus Replicates in Differentiated but Not in Undifferentiated Human Embryonal Carcinoma Cells", Science, Vol. 224, (1984), pp. 159-161.	
		B. HOGAN, "Isolation of a human teratoma cell line which expresses F9 antigen", Nature, Vol. 270, 12/1977, pp. 515-518.	
		H. JAKOB et al., TÉRATOCARCINOME DE LA SOURIS: ISOLEMENT, CULTURE ET PROPRIÉTÉS DE CELLULES A POTENTIALITÉS MULTIPLES" Ann. Microbiol. (Inst. Pasteur), 1973, 124 B, 269-282.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PT		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	09/913,853
Date Submitted: June 22, 2004		<b>Filing Date</b>	12/20/2001
(use as many sheets as necessary)		<b>First Named Inventor</b>	Peter ANDREWS
		<b>Group Art Unit</b>	1632
		<b>Examiner Name</b>	Thaian N. TON
<b>Sheet</b>	1 of 6	<b>Attorney Docket Number</b>	033236-0116

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
			WO 95/13383		Geron Corporation	5/18/1995		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Susan L. ACKERMAN et al., "Gene regulation during neuronal and non-neuronal differentiation of NTERA2 human teratocarcinoma-derived stem cells", Molecular Brain Research 25 (1994), pp. 157-162.	
		Peter W. ANDREWS et al., "Antigen Expression by Somatic Cell Hybrids of a Murine Embryonal Carcinoma Cell with Thymocytes and L Cells", Somatic Cell Genetics, Vol. 6, No. 2, 1980, pp. 271-284.	
		P.W. ANDREWS et al., "A COMPARATIVE STUDY OF EIGHT CELL LINES DERIVED FROM HUMAN TESTICULAR TERATOCARCINOMA" Int. J. Cancer, 26, pp. 269-280 (1980).	
		Peter W. ANDREWS et al., "CELL-SURFACE ANTIGENS OF A CLONAL HUMAN EMBRYONAL CARCINOMA CELL LINE: MORPHOLOGICAL AND ANTIGENIC DIFFERENTIATION IN CULTURE", Int. J. Cancer, 29, pp. 523-531 (1982).	
		Peter W. ANDREWS, "HUMAN EMBRYONAL CARCINOMA CELLS IN CULTURE DO NOT SYNTHESIZE FIBRONECTIN UNTIL THEY DIFFERENTIATE", Int. J. Cancer, 30, pp. 567-571 (1982).	
		Peter W. ANDREWS, "Retinoic Acid Induces Neuronal Differentiation of a Cloned Human Embryonal Carcinoma Cell Line in Vitro", DEVELOPMENT BIOLOGY, 103, pp. 285-293 (1984).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/913,853
Date Submitted: June 22, 2004		Filing Date	12/20/2001
(use as many sheets as necessary)		First Named Inventor	Peter ANDREWS
		Group Art Unit	1632
		Examiner Name	Thaian N. TON
		Attorney Docket Number	033236-0116
Sheet	2	of	6

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Peter W. ANDREWS et al., "Three Monoclonal Antibodies Defining Distinct Differentiation Antigens Associated With Different High Molecular Weight Polypeptides on the Surface of Human Embryonal Carcinoma Cells", HYBRIDOMA, Volume 3, Number 4, pp. 347-361 (1984).	
		Peter W. ANDREWS et al., "Pluripotent Embryonal Carcinoma Clones Derived from the Human Teratocarcinoma Cell Line Tera-2", Laboratory Investigation, Vol. 50, NO. 2, pp. 147-162 (1984).	
		Peter W. ANDREWS et al., "COMPARATIVE ANALYSIS OF CELL SURFACE ANTIGENS EXPRESSED BY CELL LINES DERIVED FROM HUMAN GERM CELL TUMORS", Int. J. Cancer, 66, pp. 806-816 (1996).	
		Peter W. ANDREWS et al., "Differentiation of TERA-2 human embryonal carcinoma cells into neurons and HCMV permissive cells", Differentiation, (1986) 31, pp. 119-126.	
		Peter W. ANDREWS et al., "Cell lines from human germ cell tumours", Teratocarcinomas and embryonic stem cells: A practical approach (E.J. Robertson, ed.), IRL Press, Oxford, pp. 207-248.	
		Peter W. ANDREWS et al., "Different patterns of glycolipid antigens are expressed following differentiation of TERA-2 human embryonal carcinoma cells induced by retinoic acid, hexamethylene bisacetamide (HMB) or bromodeoxyuridine (BUDR)", Differentiation (1990), 43: pp. 131-138.	
		Peter W. ANDREWS et al., "Inhibition of Proliferation and Induction of Differentiation of Pluripotent Human Embryonal Carcinoma Cells by Osteogenic Protein-1 (Or Bone Morphogenetic Protein 7)", Laboratory Investigation, Vol. 71, No. 2, pp. 243-251, (1994).	
		F.J. BENHAM et al., "Alkaline Phosphatase Isozymes as Possible Markers of Differentiation in Human Testicular Teratocarcinoma Cell Lines", Developmental Biology, 88, pp. 279-287 (1981).	
		Edward G. BERNSTINE et al., "Alkaline Phosphatase Activity in Mouse Teratoma", Proc. Nat. Acad. Sci., USA Vol. 70, No. 12, Part II, pp. 3899-3903 (12/1973).	
		Emiliana BORRELLI et al., "Targeting of an Inducible toxic phenotype in animal cells", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 7572-7576, October 1988.	
		Alexander BREHM et al., "Oct-4: more than just a POUerful marker of the mammalian germline?", APMIS 106 pp. 114-126 (1998).	
		David L. BRONSON et al., "Morphologic Evidence for Retrovirus Production by Epithelial Cells Derived From a Human Testicular Tumor Metastasis: Brief Communication", J. Natl. Cancer Inst., Vol. 60, No. 6, June 1978, pp. 1305-1308.	
		David L. BRONSON et al., "Cell Line Derived from a Metastasis of a Human Testicular Germ Cell Tumor", Cancer Research, 40, pp. 2500-2506, July 1980.	
		D.L. BRONSON et al., "In Vitro Differentiation of Human Embryonal Carcinoma Cells", Tetracarcinoma Stem Cells, (L.M. Silver, G.R. Martin, and S. Strickland, eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Vol. 10 (1983) pp. 597-605.	
		David L. BRONSON et al., "Production of Virions with Retrovirus Morphology by Human Embryonal Carcinoma Cells in vitro", J. Gen. Virol. (1984), 65, pp. 1043-1051.	

Examiner  
Signature


Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: June 22, 2004

(use as many sheets as necessary)

Sheet 4 of 6

**Complete if Known**

Application Number	09/913,853
Filing Date	12/20/2001
First Named Inventor	Peter ANDREWS
Group Art Unit	1632
Examiner Name	Thaian N. TON
Attorney Docket Number	033236-0116

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		A.J. JEFFREYS et al., "Individual-specific 'fingerprints' of human DNA", Nature, Vol. 316, 7/1985, PP. 76-79.	
		Alec J. JEFFREYS et al, "Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells", Nucleic Acid Research, Vol. 16, Number 23, 1988, pp. 10953-10971.	
		Reiji KANNAGI et al., "New Globoseries Glycosphingolipids in Human Teratocarcinoma Reactive with the Monoclonal Antibody Directed to a Developmentally Regulated Antigen, Stage-specific Embryonic Antigen 3" The Journal of Biological Chemistry, Vol. 258, No. 14, Issue of July 25, 1983, pp. 8934-8942.	
		Roger H. KENNETT, "[28] Cell Fusion" Methods in Enzymology, Vol. 58, pp. 345-359.	
		Yasuhisa MATSUI et al., "Derivation of Pluripotential Embryonic Stem Cells from Murine Primordial Germ Cells in Culture", Cell, Vol. 70, 9/1992, pp. 841-847.	
		Fulvio MAVILIO et al., "Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid", Differentiation (1988) 37:73-79.	
		James W. McCARRICK et al., "Embryonal carcinoma cells and embryonic stem cells as models for neuronal development and function", (1992), In: Cell Lines in Neurobiology: A Practical Approach (J. Woods, Ed), IRC Press, Oxford, pp. 77-104.	
		W.H. MILLER Jr. et al., "Growth Factors in Human Germ Cell Cancer", Recent Results in Cancer Research, Vol. 123, (1991), pp. 183-189.	
		Garry A. NEIL et al., "[14] Electrofusio", Methods in Enzymology, Vol. 220, pp. 174-196 (1993).	
		G. POSTE et al., "Formation of Hybrid Cells and Heterokaryons by Fusion of Enucleated and Nucleated Cells", Nature New Biology, Vol. 229, January 1971, pp. 123-125.	
		G. POSTE, "ENUCLEATION OF MAMMALION CELLS BY CYTOCHALASIN B", Experimental Cell Research 73 (1972) pp. 273-286.	
		D.M. PRESCOTT et al., "Enucleation of mammalian cells with cytochalasin B", Exptl. Cell Res. 71, pp. 480-485.	
		Elizabeth ROBERTSON, "Embryo-derived stem cells lines", (1987), Teratorcarcinomas and embryonic stem cells: A practical approach (Robertson, E.J., Editor), IRL Press, Oxford, pp. 71-112.	
		Edward ROSFJORD et al., "THE OCTAMER MOTIF PRESENT IN THE REX-1 PROMOTER BINDS OCT-1 AND OCT-3 EXPRESSED IN EC CELLS AND ES CELLS", Biochemical and Biophysical Research Communications, Vol. 203, No. 3, 1994, pp. 1795-1802.	
		Michael J. SHAMBLOTT et al., "Derivation of pluripotent stem cells from cultured human primordial germ cells", Proc. Natl. Acad. Sci. USA, Vol. 95, 11/1998, pp. 13726-13731.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: June 22, 2004

(use as many sheets as necessary)

Sheet 5 of 6

**Complete if Known**

Application Number	09/913,853
Filing Date	12/20/2001
First Named Inventor	Peter ANDREWS
Group Art Unit	1632
Examiner Name	Thaia N. TON
Attorney Docket Number	033236-0116

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Jerry W. SHAY, "[17] Cell Enucleation, Cybrids, Reconstituted Cells, and Nuclear Hybrids", Cell Enucleation, 151, pp. 221-237 (1987).	
		Jerry W. SHAY, "Selection of reconstituted cells from karyoplasts fused to chloramphenicol resistant cytoplasts", Proc. Natl. Acad. Sci. USA, Vol. 74, No. 6, pp. 2461-2464.	
		Lynne Hamburger SHEVINSKY et al., "Monoclonal Antibody to Murine Embryos Defines a Stage-Specific Embryonic Antigen Expressed on Mouse Embryos and Human Teratocarcinoma Cells", Cell, Vol. 30, (1982), pp. 697-705.	
		Antonio SIMEONE et al., "Sequential activation of <i>HOX2</i> homeobox genes by retinoic acid in human embryonal carcinoma cells", NATURE, Vol. 346, 8/1990, pp. 763-766.	
		Davor SOLTER et al., "Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1)", Proc. Natl. Acad. Sci. USA, Vol. 75, No. 11, pp. 5565-5569.	
		Shirley M. TAYLOR et al., "Multiple New Phenotypes Induced in 10T1/2 and 3T3 Cells Treated with 5-Azacytidine", Cell, Vol. 17, pp. 771-779, 8/1979.	
		Shinichi TESHIMA et al., "Four New Human Germ Cell Tumor Cell Lines", Laboratory Investigation, Vol. 59, No. 3, pp. 328-336, (1988).	
		James A. THOMSON et al., "Isolation of a primate embryonic stem cell line" Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 7844-7848, 8/1995.	
		James A. THOMSON et al., "Embryonic Stem Cell Lines Derived from Human Blastocysts", SCIENCE, Vol. 282, 11/1998, pp. 1145-1147.	
		S. THOMPSON et al., "CLONED HUMAN TERATOMA CELLS DIFFERENTIATE INTO NEURON-LIKE CELLS AND OTHER CELL TYPES IN RETINOIC ACID", J. Cell. Sci., 72, 37-64, (1984).	
		Akihiro UMEZAWA et al., "Methylation of an ETS Site in the Intron Enhancer of the Keratin 18 Gene Participates in Tissue-Specific Repression", Molecular and Cellular Biology, Vol. 17, No. 9, 9/1997, p. 4885-4894.	
		George VEOMETT et al., "Reconstruction of Mammalian Cells from Nuclear and Cytoplasmic Components Separated by Treatment with Cytochalasin B", Proc. Nat. Acad. Sci. USA, Vol. 71, No. 5, pp. 1999-2002, (5/1974).	
		Nicholas VOGELZANGE et al., "AN EXTRAGONADAL HUMAN EMBRYONAL CARCINOMA CELL LINE", (1983), Proc. Am. Assoc. Cancer Res. 24, 3 *ABSTRACT*.	
		T. WAKAYAMA et al., "Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei", NATURE, vol. 394, 7/1998, pp. 369-374.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: June 22, 2004

(use as many sheets as necessary)

Sheet 6 of 6

**Complete if Known**

Application Number	09/913,853
Filing Date	12/20/2001
First Named Inventor	Peter ANDREWS
Group Art Unit	1632
Examiner Name	Thaian N. TON
Attorney Docket Number	033236-0116

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Jane A. WAKEMAN et al., "MAL mRNA is induced during the differentiation of human embryonal carcinoma cells into neurons and is also localised within specific regions of the human brain", Differentiation (1997) 62, pp. 97-105.	
		Jame A. WAKEMAN et al., "Human <i>Wnt-13</i> is developmentally regulated during the differentiation of NTERA-2 pluripotent human embryonal carcinoma cells", Oncogene (1998), 17, pp. 179-186.	
		Nancy WANG et al., "Nonrandom Abnormalities in Chromosome 1 in Human Testicular Cancers", CANCER RESEARCH 40, pp. 796-802, (3/1980).	
		Nancy WANG et al., "Cytogenetic Evidence for Premeiotic Transformation of Human Testicular Cancers", CANCER RESEARCH, 41, pp. 2135-2140, (6/1981).	
		Jonathan WENK et al, "GLYCOLIPIDS OF GERM CELL TUMORS: EXTENDED GLOBO-SERIES GLYCOLIPIDS ARE A HALLMARK OF HUMAN EMBRYONAL CARCINOMA CELLS", Int. J. Cancer: 58, pp. 108-115 (1994).	
		Michael H. WIGLER et al., "A PREPARATIVE METHOD FOR OBTAINING ENUCLEATED MAMMALIAN CELLS", Biochemical and Biophysical Research Communications, Vol. 63, No. 3, (1975), pp. 669-674.	
		B.P. WILLIAMS et al., "Biochemical and genetic analysis of the Ok <sup>a</sup> blood group antigen", Immunogenetics 27, (1988), pp. 322-329.	
		Woodring E. WRIGHT et al., "Enucleation of Cultured Human Cells (37640)", (1973), Proc. Soc. Exp. Biol. Med. 144, pp. 587-592.	
		Woodring E. WRIGHT et al., "Use of Biochemical Lesions for Selection of Human Cells with Hybrid Cytoplasms", Proc. Nat. Acad. Sci. USA, Vol. 72, No. 5, pp. 1812-1816, (5/1975).	
		Rui YAN et al., "DNA FINGERPRINTING OF HUMAN CELL LINES USING PCR AMPLIFICATION OF FRAGMENT LENGTH POLYMORPHISMS", In Vitro Cell. Dev. Biol.--Animal, 32, pp. 656-662 (11/1996).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.